Niagen Bioscience, Inc. (NAGE)
| Market Cap | 237.88M -69.0% |
| Revenue (ttm) | 129.08M +11.0% |
| Net Income | 15.99M -9.8% |
| EPS | 0.19 -11.7% |
| Shares Out | 79.29M |
| PE Ratio | 15.78 |
| Forward PE | 32.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,787 |
| Open | 3.010 |
| Previous Close | 3.000 |
| Day's Range | 2.980 - 3.050 |
| 52-Week Range | 2.870 - 10.520 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 12.08 (+302.67%) |
| Earnings Date | Nov 3, 2026 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-gra... [Read more]
Financial Performance
In 2025, Niagen Bioscience's revenue was $129.42 million, an increase of 29.95% compared to the previous year's $99.60 million. Earnings were $17.38 million, an increase of 103.30%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $12.08, which is an increase of 302.67% from the latest price.
News
Niagen Bioscience to Present at Canaccord Genuity's Well Summit
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience to Present at Longevity Investors Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience Transcript: 17th Annual Midwest IDEAS Conference
The presentation highlighted strong financials, robust patent protection, and leadership in NAD-boosting products for aging, with expanding e-commerce, new product launches, and a promising drug pipeline. NB4168 is advancing toward clinical trials, with first-in-human studies expected in 2027.
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy agin...
Niagen Bioscience expands Tru Niagen footprint with GNC, Sam’s Club
Niagen Bioscience (NAGE) announced that Tru Niagen is now available at GNC and Sam’s Club (WMT) retail locations and online.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir
In an exclusive interview, Niagen Bioscience’s (NAGE) CFO Ozan Pamir spoke with The Fly about the company’s evolving NAD focused strategy, the stability of its core business, and how its…
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience Transcript: Canaccord Genuity's 46th Annual Growth Conference
Niagen Bioscience leads in NAD+ science, with strong supplement and ingredient sales, expanding into skincare and IV products. Recent studies highlight anti-aging benefits, and the company maintains a robust financial position while investing in R&D and rare disease therapies.
Niagen Bioscience CFO highlights telehealth as ‘high-expectation growth channel’
14:00 EDT Niagen Bioscience (NAGE) CFO highlights telehealth as ‘high-expectation growth channel’
Bananas, Bread, Bones…Walmart Seals Healthy Aging Deal With Niagen Bioscience
Walmart ($WMT) customers can now add something new to their shopping list of bananas, bread and beans – a healthy aging supplement from Niagen Bioscience ($NAGE). Available on Walmart.com Shares…
Niagen Bioscience announces Tru Niagen is now available at Walmart
Niagen Bioscience (NAGE) announced that Tru Niagen is now available at Walmart.com (WMT). “Expanding Tru Niagen’s availability on Walmart.com makes our science-backed NAD+ solution more accessible to ...
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience price target lowered to $10 from $12 at Roth Capital
Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $10 from $12 and keeps a Buy rating on the shares. The company reported better than expected Q2…
Niagen Bioscience Earnings Call Transcript: Q2 2026
Q2 2026 revenue reached $29.8M, with strong e-commerce and China growth, stable gross margin, and continued profitability. Expansion into skincare, IV/injection, and pharmaceuticals is underway, with NB4168 advancing and major revenue growth in Niagen Plus expected in 2027.
Niagen Bioscience Earnings release: Q2 2026
Niagen Bioscience released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Niagen Bioscience Quarterly report: Q2 2026
Niagen Bioscience has published its Q2 2026 quarterly earnings report on August 4, 2026.
Niagen Bioscience Slides: Q2 2026
Niagen Bioscience has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Niagen Bioscience sees ecommerce business growing 10%-15% in FY26
The company said, “For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year. We continue to expect the remainder of our consumer business…
Niagen Bioscience reports Q2 EPS 1c vs 4c last year
Reports Q2 revenue $29.8M, consensus $30.53M. “During the quarter, Tru Niagen continued to demonstrate its category leadership, and at the same time, we laid the foundation strategically for what we…
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Fin...
Niagen Bioscience selects Evotec to advance development for NB4168
Niagen Bioscience (NAGE) announced that it has selected Evotec (EVO) as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD…
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience announces publication on muscle epigenetic age
Niagen Bioscience (NAGE) announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen supplementation was associated with reduced mu...
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BiologicalAge--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy a...